Status:
UNKNOWN
Analysing the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke
Lead Sponsor:
Dongzhimen Hospital, Beijing
Collaborating Sponsors:
Affiliated Hospital of Nantong University
Nanjing Brian Hospital
Conditions:
Acute Stroke
Ischemic Stroke
Eligibility:
All Genders
35-80 years
Phase:
NA
Brief Summary
The main purpose of this trial is to analyse the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke by Metabonomics, proteomics and clinical parameters.
Detailed Description
Xingnaojing is widely used in China, but there is lack of sufficient and reasonable explanation of its intervention effects for acute ischemic stroke currently. The primary hypothesis of this trial is...
Eligibility Criteria
Inclusion
- Diagnosis of Acute ischemic stroke；
- Symptom onset within 24 hours；
- 35 ≤ Age ≤ 80 years；
- 4 ≤ NIHSS ≤ 25；
- Patient or legally authorized representative has signed informed consent.
Exclusion
- Expected length of hospital stay is less than 10 days;
- Planned or already receiving intravenous thrombolysis or endovascular treatment;
- Use of drugs with unknown composition within 1 week before enrollment;
- Patients with acute infectious diseases (e.g. acute pneumonia) or taking related drugs within 1 month before treatment in the group;
- Suspected secondary stroke caused by tumor, brain trauma, or hematological diseases;
- Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scale score ≥ 2) ;
- Other conditions that cause cardiogenic embolism (e.g., atrial fibrillation, rheumatic heart disease, valvular heart disease);
- Other conditions that lead to motor dysfunction (e.g., severe osteoarthrosis, rheumatoid arthritis);
- Significant renal or hepatic insufficiency (defined as a serum creatinine concentration, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) value that is twice the upper limit of normal);
- Life expectancy of 3 months or less due to other life-threatening illness (e.g.,advanced cancer)
- Other conditions that render outcomes or follow-up unlikely to be assessed;
- Known to be pregnant or breastfeeding;
- Currently receiving an investigational drug.
Key Trial Info
Start Date :
May 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 28 2022
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04813445
Start Date
May 28 2021
End Date
September 28 2022
Last Update
February 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dongzhimen Hospital
Beijing, Beijing Municipality, China, 100700